Join the Glaucoma group to help and get support from people like you.
Glaucoma News
NRTI Use Linked to Risk for Primary Open-Angle Glaucoma
TUESDAY, July 8, 2025 – Use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) is associated with an increased risk for primary open-angle glaucoma (POAG), according to a study...
Drop in Mental Health Scores Seen With Primary Open-Angle Glaucoma Diagnosis
MONDAY, June 9, 2025 – Diagnosis of primary open-angle glaucoma (POAG) is associated with a reduction in mental health scores, according to a study published online June 5 in JAMA Ophthalmology. Mae...
Swept-Source Anterior Segment OCT Can Help Distinguish Early Childhood Glaucoma
FRIDAY, May 23, 2025 – The noninvasive swept-source anterior-segment optical coherence tomography (SS-ASOCT) can diagnose early-onset childhood glaucoma, according to a study published online May 22...
'Good' Cholesterol Could Be Bad For Glaucoma
WEDNESDAY, Feb. 5, 2025 – The cholesterol that’s good for your heart health might be bad for your eye health, and vice versa, a new study says. “Good” HDL cholesterol appears to increase risk of glau...
Elevated HDL Cholesterol Linked to Increased Risk for Glaucoma
WEDNESDAY, Feb. 5, 2025 – Elevated high-density lipoprotein cholesterol (HDL-C) is associated with an increased risk for glaucoma, while elevated low-density lipoprotein cholesterol (LDL-C), total...
Access to Ophthalmic Specialty Care Increasingly Challenging in Rural Areas
FRIDAY, Jan. 3, 2025 – Rural areas are increasingly facing ophthalmic subspecialty surgeon shortages, according to a study published online Jan. 2 in JAMA Ophthalmology. Aishah Ahmed, from the Johns ...
1.5 Million U.S. Adults Have Vision-Affecting Glaucoma
FRIDAY, Oct. 18, 2024 – An estimated 2.56 percent of U.S. adults ages 40 years and older have glaucoma, according to a study published online Oct. 17 in JAMA Ophthalmology. Joshua R. Ehrlich, M.D., ...
Free Eye Disease Screening Program Engaging High-Risk Adults
TUESDAY, Aug. 27, 2024 – A novel free eye disease screening program is engaging adults at high risk for eye disease who are underusing eye care services, according to a study published online Aug....
FDA Medwatch Alert: FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products
September 12, 2023 – The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal...
FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
Iyuzeh™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LE...
FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension
EMERYVILLE, Calif. & UBE, Japan--(BUSINESS WIRE) September 26, 2022 --Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the...
FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
DUBLIN, March 5, 2020 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug...
FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension
DURHAM, N.C.--(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and...
FDA Approves Xelpros (latanoprost ophthalmic emulsion) to Treat Open-angle Glaucoma or Ocular Hypertension
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE) September 14, 2018 --Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) today announced U.S. Food and Drug...
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for Patients with Open-Angle Glaucoma or Ocular Hypertension
IRVINE, Calif.--(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and...